Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

2.

Structural identification and biological activity of positional isomers of long-acting and mono-PEGylated recombinant human granulocyte colony-stimulating factor with trimeric-structured methoxy polyethylene glycol N-hydroxysuccinimidyl functional group.

Son JP, Jun SW, Choi YK, Park HS, Son MK, Lee MY, Kang SH, Kang JS, Park YI.

Anal Biochem. 2012 Apr 15;423(2):286-93. doi: 10.1016/j.ab.2011.12.014. Epub 2011 Dec 26.

PMID:
22244804
5.

Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.

Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano K.

Cancer Res. 1991 Jul 15;51(14):3710-4.

6.

Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight.

Zhai Y, Zhao Y, Lei J, Su Z, Ma G.

J Biotechnol. 2009 Jul 15;142(3-4):259-66. doi: 10.1016/j.jbiotec.2009.05.012. Epub 2009 Jun 2.

PMID:
19497340
7.

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.

Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9. Chinese.

PMID:
17313855
8.

Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Scholz M, Engel C, Apt D, Sankar SL, Goldstein E, Loeffler M.

Cell Prolif. 2009 Dec;42(6):823-37. doi: 10.1111/j.1365-2184.2009.00641.x. Epub 2009 Sep 24.

PMID:
19780759
9.

Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. Pharmacokinetic and activity studies of single-dose administration in mice.

Rotondaro L, De Paolis E, Ferrero D, D'Alatri L, Raucci G, Fabbri A, Gerwig GJ, Kamerling JP, Mariani MF, Mele A, De Santis R.

Mol Biotechnol. 1999 Apr;11(2):117-28.

PMID:
10464766
11.
12.
13.

[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].

Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.

Ai Zheng. 2006 Apr;25(4):495-500. Chinese.

PMID:
16613688
14.
15.

Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys.

Tanaka H, Tanaka Y, Shinagawa K, Yamagishi Y, Ohtaki K, Asano K.

Cytokine. 1997 May;9(5):360-9.

PMID:
9195136
17.

An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.

Shin KH, Lim KS, Lee H, Jang IJ, Yu KS.

Invest New Drugs. 2014 Aug;32(4):636-43. doi: 10.1007/s10637-014-0068-7. Epub 2014 Jan 28.

PMID:
24468886
18.
19.
20.

The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure.

Akizawa T, Shishido K, Koshikawa S.

Artif Organs. 1995 Dec;19(12):1251-7.

PMID:
8967884

Supplemental Content

Support Center